This Week’s Top Capital Growth Dividend Stocks

⭐ For Premium Partners Only

Inside the MaxDividends framework, every series has a job.

This series is about capital growth first. Here we focus on companies where capital appreciation leads the story, and dividends serve as a quality filter.

These are businesses that reinvest intelligently, expand earnings power, grow intrinsic value — and because of that, pay and raise dividends over time.

Capital grows first. Income follows.

Every company in this series is selected through the MaxDividends Income System.

The MaxDividends Income System is our filter, rulebook, logic, and decision-making checklist — the framework that determines what belongs in a long-term compounding portfolio and what doesn’t.

For Capital Growth Dividend Stocks, the System is applied with a clear priority: capital growth first, dividends as confirmation of quality.

We run each candidate through the MaxDividends Income System, which for this series includes the following core criteria:

Strong balance sheet, durable margins, clean cash flows, and consistent execution across cycles. A foundational quality check covering business durability, competitive position, capital allocation discipline, and long-term compounding ability.

Not for yield — but as proof that the business generates real cash and management allocates it responsibly.

A profile that reflects capital efficiency, reinvestment quality, and long-term compounding potential.

Know when the price makes sense. See at a glance whether a stock is fairly valued, undervalued, or overpriced. Only fairly valued or undervalued companies qualify. Even great growth stories fail if you overpay.

The whole investment case in one glance. Valuation, investment consensus, and the stock’s best role in your portfolio.

The MaxDividends Research Platform supports this process as our central data hub and navigator.

It stores the full history behind every decision — fundamentals, dividend timelines, valuation ranges, portfolio structure — and lets us track where we are, how far we’ve come, and whether we’re still aligned with the System.

The System decides. The Platform records, visualizes, and keeps us on course.

That’s how we consistently identify businesses where capital growth leads, dividends validate quality, and long-term wealth compounds quietly — week after week.

That’s where we are now.

This week’s Capital Growth Dividend list highlights businesses with durable earnings engines, pricing power, disciplined balance sheets, and long runways for both capital appreciation and rising income.

☕️ Pour your coffee, tune out the noise, and lean into the process — the best capital-growth dividend opportunities rarely announce themselves loudly.

⭐ Scroll to read — you’re a Premium partner, and the full breakdown is yours

👉 Here’s what made this week’s Capital Growth radar.

Your Essential Dividend Investing Guide

👉 Let’s start with this week’s Top 3 Capital Growth Dividend picks — the names that stand out most right now as potential foundation stones for long-term capital growth.

FactSet provides financial data, analytics, research tools, and workflow technology used by investment managers, banks, wealth managers, and other financial professionals. Its platform combines proprietary and third-party data with analytics and software that become deeply embedded in clients’ day-to-day investment processes.

That creates a highly recurring business model with strong customer retention and significant switching costs. FactSet is also expanding beyond traditional financial data into AI-powered workflows, enterprise data infrastructure, and real-time market-data technology — increasing the number of ways it can grow within existing client relationships. FactSet reports more than 9,100 global clients and 247,000 individual users.

Brown & Brown is one of the largest insurance brokerage and risk-management companies in the United States. Rather than taking insurance risk onto its own balance sheet, the company primarily earns commissions and fees by helping businesses and individuals find insurance coverage and manage risk.

The model combines recurring insurance demand with a highly fragmented brokerage market, giving Brown & Brown two long-term growth engines: organic expansion within its existing operations and acquisitions of smaller insurance agencies and specialized brokers. That acquisition strategy has been a central part of the company’s growth model for decades.

Stryker is one of the world’s largest medical-technology companies, with businesses spanning orthopaedics, surgical equipment, neurotechnology, endoscopy, emergency care, and other hospital technologies. Its products are used across operating rooms and healthcare systems worldwide, reaching more than 150 million patients annually.

The company benefits from several durable healthcare trends, including aging populations, rising procedure volumes, greater adoption of robotic and digitally assisted surgery, and continued investment by hospitals in equipment that can improve clinical outcomes and operating efficiency.

This week’s lineup highlights elite dividend-paying compounders — companies where capital growth leads the story and dividends quietly reinforce the long-term track.

We track them inside a model portfolio—adding one stock at a time, week after week.

⭐️ Week 09/29/2026 | MaxDividends USA Picks

👉 Top 10 Capital Growth Focused (USA) – Model Portfolio Performance

Capital Growth Focused

Dover and Brady bring a strong industrial angle to this week’s list. Dover raised its full-year 2026 adjusted EPS guidance after a solid second quarter, supported by organic growth across its portfolio, while Brady continues to offer a combination of recurring identification and safety-product demand, disciplined capital allocation, and a long dividend-growth record.

Nucor stands out as the cyclical name in the group, with business conditions improving into the third quarter. Management now expects Q3 earnings of $5.55–$5.65 per share, up from $5.04 in Q2, with higher selling prices and stable volumes supporting stronger results in both steel mills and steel products.

Healthcare and defensive businesses add balance. Chemed continues to combine its VITAS hospice business with Roto-Rooter, while Church & Dwight raised its full-year organic sales outlook to 4%–5% after second-quarter organic growth of 5.8%. Globe Life continues to deliver strong premium and earnings growth, with health premiums up 16% in Q2 and management raising its full-year earnings outlook.

Technology remains represented by three familiar capital-growth businesses. Applied Materials and KLA continue to benefit from increasingly complex AI-related semiconductor manufacturing, particularly advanced logic, memory, and packaging. Applied recently reported record quarterly revenue of $9.12 billion, while KLA posted record fiscal Q4 revenue of $3.66 billion and expects business momentum to continue into 2027. Microsoft provides exposure to the same AI investment cycle through cloud and software, with fiscal Q4 revenue growing 18% to $90 billion.

Morningstar rounds out the list with a different type of compounding model: financial data, research, indexes, and investment tools built around recurring demand from investors and financial institutions.

This week’s Top 10 is just the start—hundreds of battle-tested dividend growers with serious capital growth potential are waiting in the full Dividend Eagles list inside the MaxDividends Research Platform.

Here are the names purchased in Q3 ’26:

Donaldson is a global leader in filtration systems used across industrial equipment, transportation, aerospace, and life sciences. The company benefits from a large installed base and recurring replacement demand, supporting steady cash flow and consistent long-term growth.

IDEX manufactures highly engineered products used in healthcare, industrial, water, and scientific applications. Its portfolio of niche market leaders, combined with disciplined acquisitions and strong margins, has made IDEX a reliable long-term compounder.

Lindsay is a leading provider of irrigation equipment and transportation infrastructure solutions. The business is supported by long-term demand for water efficiency, agricultural productivity, and infrastructure investment, providing a solid foundation for future growth.

Aptar specializes in dispensing and packaging solutions used across healthcare, beauty, and consumer products. The business is supported by recurring demand, innovation, and long-term customer relationships, creating a solid foundation for steady growth.

Gorman-Rupp designs and manufactures pumps used in water, wastewater, construction, industrial, and municipal applications. The company serves essential infrastructure markets, generating resilient cash flow and supporting steady long-term dividend growth.

Kids’ Portfolios:

These aren’t just household U.S. names—this week we spotlight three global dividend growers that have quietly crushed the market while rewarding investors with rising payouts. Each one combines serious capital growth potential with the kind of dividend discipline that builds real long-term wealth.

👇 Let’s break down the top 3 international picks — and if you want the full runway of global Dividend Eagles, you’ll find the complete updated list inside the MaxDividends Research Platform.

⭐️ Week 09/29/2026 | MaxDividends International Stocks

UCB is a Belgian biopharmaceutical company focused primarily on severe diseases in immunology and neurology. Its portfolio includes treatments for psoriasis, psoriatic arthritis, hidradenitis suppurativa, epilepsy, myasthenia gravis, and osteoporosis, supported by an expanding pipeline of next-generation therapies.

The company is currently moving through an important growth cycle as newer products become a larger part of the business. BIMZELX has emerged as its most important growth engine, while RYSTIGGO, ZILBRYSQ, FINTEPLA, and EVENITY provide additional sources of expansion across immunology and neurology.

Porvair is a specialist filtration and environmental technology company serving aerospace, energy, industrial, laboratory, and environmental markets. Its filtration systems and analytical products are typically used in applications where reliability, safety, and precise performance are critical.

The company operates through specialized businesses serving relatively small but technically demanding markets. That niche-focused model, combined with disciplined acquisitions and a strong balance sheet, has allowed Porvair to steadily compound earnings while maintaining a long record of dividend growth.

Kurita Water Industries is a Japanese water-treatment company providing chemicals, equipment, maintenance, and water-management solutions to industrial customers. Its technologies are used across semiconductor manufacturing, electronics, general industry, and other operations where water quality, recycling, and efficient resource use are critical.

The business is increasingly positioned around higher-value recurring services and solutions rather than simply selling water-treatment equipment. Semiconductor manufacturing is particularly important because advanced chip production requires enormous quantities of ultra-pure water and increasingly sophisticated systems for treatment, recovery, and reuse.

The 3 picks we just covered are only the start. Beyond them, there’s a whole roster of global Dividend Eagles—companies that have raised payouts for 15+ years and kept shareholders winning across every cycle.

Explore the full updated International Dividend Eagles list now inside the MaxDividends Platform — your runway to the world’s most consistent wealth compounding machines.

Research-backed guidance on quality dividend stocks.

Every week we analyze thousands of companies across the MaxDividends Universe, evaluating them using Financial Scores, MaxRatio, valuation, dividend discipline, and long-term earnings trends.

The result is a clear Buy / Hold / Sell breakdown of the top dividend names in the market. Just a data-driven snapshot that shows:

It's the fastest way to understand where quality is strengthening — and where it's fading.

A quick roundup of articles and dividend stock ideas worth your time.

Every week, some of our Dividend Eagles spread their wings a little wider. These are the names that delivered the strongest price gains on the market—proof that reliable dividend payers don’t just hand out income, they can also fly high on capital growth.

👉 Here are this week’s top 3 gainers from the Dividend Eagles list:

Every week, some of our Dividend Eagles spread their wings a little wider. These are the names that delivered the strongest price gains on the market—proof that reliable dividend payers don’t just hand out income, they can also fly high on capital growth.

👉 Here are this week’s top 3 gainers from the Dividend Eagles list:

Applied Materials is one of the world’s largest suppliers of semiconductor manufacturing equipment, providing technologies used in chip fabrication, materials engineering, inspection, and advanced packaging.

Shares moved higher as semiconductor-equipment stocks rallied on continued optimism around AI infrastructure spending and demand for more advanced chipmaking tools. Applied is also expanding its long-term manufacturing and R&D footprint, while strong demand for leading-edge logic, memory, and advanced packaging continues to support the broader growth story.

KLA develops inspection, metrology, and process-control systems that help semiconductor manufacturers identify defects and improve yields throughout increasingly complex chip-production processes.

KLA’s rally reflects growing investor attention on the semiconductor-equipment layer of the AI buildout. More advanced logic, HBM, EUV manufacturing, and advanced packaging all require greater process-control intensity, directly expanding demand for KLA’s technologies. The company expects second-half 2026 revenue to run roughly 20% above the first half, with management seeing momentum continuing into 2027.

West Pharmaceutical Services supplies high-value components and delivery systems used in injectable medicines, biologics, GLP-1 therapies, and other drug-delivery applications.

West continues to gain momentum as investors respond to stronger growth expectations. Second-quarter organic sales increased 12.7%, adjusted EPS rose 28.8%, and management raised full-year organic growth guidance to 10%–11%. Demand remains particularly strong across high-value components, biologics, GLP-1 elastomers, and regulatory-driven Annex 1 upgrades, helping reinforce the company’s improving growth outlook.

Happy dividends for all the holders!

Best regards,
Max

💌 Questions or thoughts? Reach me anytime at [email protected]

⭐️ Private • For Premium Partners Only

Learn the MaxDividends Way